Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Oduru G, Amongin R, Kabuubi PN, Mutebe A, Onen C, Amongi S, Nakazibwe E, Akello F, Kiwanuka S, Kiwudhu F, Sewankambo M, Nsubuga D, Kizindo R, Staedke SG, Cose S, Webb E, Elliott AM; POPVAC trial team. Natukunda A, et al. BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427. BMJ Open. 2021. PMID: 33593769 Free PMC article.
Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.
Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Ninsiima C, Zziwa C, Akello F, Kizindo R, Akello M, Kaleebu P, Wajja A, Luzze H, Cose S, Webb E, Elliott AM; POPVAC trial team. Nkurunungi G, et al. Among authors: natukunda a. BMJ Open. 2021 Feb 16;11(2):e040425. doi: 10.1136/bmjopen-2020-040425. BMJ Open. 2021. PMID: 33593767 Free PMC article.
Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Nkurunungi G, Zirimenya L, Nassuuna J, Natukunda A, Kabuubi PN, Niwagaba E, Oduru G, Kabami G, Amongin R, Mutebe A, Namutebi M, Zziwa C, Amongi S, Ninsiima C, Onen C, Akello F, Sewankambo M, Kiwanuka S, Kizindo R, Kaweesa J, Cose S, Webb E, Elliott AM; POPVAC trial team; POPVAC trial team principal investigator. Nkurunungi G, et al. Among authors: natukunda a. BMJ Open. 2021 Feb 16;11(2):e040426. doi: 10.1136/bmjopen-2020-040426. BMJ Open. 2021. PMID: 33593768 Free PMC article.
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb E, Elliott AM; POPVAC trial team. Zirimenya L, et al. Among authors: natukunda a. BMJ Open. 2021 Feb 16;11(2):e040430. doi: 10.1136/bmjopen-2020-040430. BMJ Open. 2021. PMID: 33593770 Free PMC article.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: natukunda a. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: natukunda a. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
15 results